NCT07177872

A Long-term Efficacy and Safety of NTQ5082 Capsules

A Multicenter, Open-label Study Evaluating the Long-term Efficacy and Safety of NTQ5082 Capsules in the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 78 (estimated)
• Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

NTQ5082 capsules are a small molecule CFB inhibitor. This study is a multicenter, open-label study evaluating the long-term efficacy and safety of NTQ5082 capsules in the treatment of patients with paroxysmal nocturnal hemoglobinuria

Conditions

• Paroxysmal Nocturnal Hemoglobinuria

Interventions

Type	Name	Description
DRUG	NTQ5082 capsules 200 mg	NTQ5082 capsules 200 mg

Timeline

• Start date: 2026-06-01
• Primary completion: 2028-06-01
• Completion: 2028-06-01
• First posted: 2025-09-17
• Last updated: 2025-09-17

Locations

1 site across 1 country: China